This coming Friday, September 20, Wake Up Narcolepsy, a non-profit dedicated to raising awareness for narcolepsy, will host its inaugural Shadows To Light Gala 2024. The event will feature an educational forum preceding the gala, a live and silent auction, as well as dinner and plenty of entertainment. In anticipation of this event, sleep expert Dr. Anne Marie Morse detailed all aspects of gala, and how it can drive awareness and education toward patients, providers, and families dealing with narcolepsy.
Advertisement
Researchers have developed a machine learning model which can identify people who are likely to have elevated Lp(a).
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
A new study finds that 3D digital breast tomosynthesis is more effective at detecting BC than traditional 2D.
Researchers presented an updated safety and efficacy analysis at the ESMO 2024 Congress.
Gala aimed at raising awareness for narcolepsy launches silent auction comprised of almost 70 lots.
The ASN for the first time has issued guidance on the management of obesity in persons with kidney diseases.
Bempedoic acid treatment is similarly effective at lowering low-density lipoprotein cholesterol compared with statins.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Retifanlimab plus chemotherapy showed improved PFS and response rates in locally recurrent or metastatic SCAC.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
FLOT and nivo seems to be associated with improved efficacy, whereas chemo followed by IO therapy is insufficient.
The Latest From Heme Today
Levels for certain inflammation biomarkers in patients with MDS were similar to in patients with autoinflammatory disorders.
In pediatric, adolescent, and young adult patients, hematopoietic stem cell transplant was found to bolster overall survival.
The most common serious treatment-emergent adverse event among patients receiving either therapy was pneumonia.
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
